Key takeaways:

A 6-week corticosteroids regimen significantly improved treatment success for immune-related pneumonitis compared with a 3-week regimen.

The regimen also significantly reduced the rate of relapse.

CHICAGO — A guideline-recommended 6-week regimen of corticosteroids for pneumonitis associated with immunotherapy significantly improved outcomes compared with a 3-week regimen, according to findings presented at ASCO Annual Meeting.

Patients who received standard care had a treatment success rate approximately 18% greater than the 3-week arm, as well as a lower rate of relapse and improved quality of life.

Data derived from Fujimoto D, et al. Abstract 12006. Presented at: ASCO Annual Meeting; May 30-June 3, 2024; Chicago.

“The 6-week corticosteroid regimen endorsed by the gu

See Full Page